Theravet SA (ALVET)

Currency in EUR
0.08
0.00(0.00%)
Closed·
Showing Theravet historical data. For real-time data please try another search
Fair Value
Day's Range
0.080.08
52 wk Range
0.060.79
Key Statistics
Prev. Close
0.08
Open
0.08
Day's Range
0.08-0.08
52 wk Range
0.06-0.79
Volume
-
Average Volume (3m)
21.83K
1-Year Change
-68.99%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALVET Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Theravet SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell

Theravet SA Company Profile

TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species specific plasma, and an active pharmaceutical component. The company also provides various products, such as BIOCERA-VET bone surgery RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement; BIOCERA-VET smartgraft, a naturally osteoconductive bone graft; BIOCERA-VET granules, an affordable biocompatible calcium-phosphate bone substitute; and BIOCERA-VET osteosarcoma RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty. The company was incorporated in 2017 and is based in Gosselies, Belgium.

Compare ALVET to Peers and Sector

Metrics to compare
ALVET
Peers
Sector
Relationship
P/E Ratio
0.0x−4.2x−0.5x
PEG Ratio
0.000.030.00
Price/Book
0.0x1.0x2.6x
Price / LTM Sales
0.0x8.3x3.2x
Upside (Analyst Target)
0.0%102.7%42.0%
Fair Value Upside
Unlock5.1%6.6%Unlock

Earnings

Latest Release
Sep 12, 2024
EPS / Forecast
-0.26 / --
Revenue / Forecast
450.41K / --
EPS Revisions
Last 90 days

ALVET Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.